60 related articles for article (PubMed ID: 1282613)
21. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial.
Amit G; Cafri C; Yaroslavtsev S; Fuchs S; Paltiel O; Abu-Ful A; Weinstein JM; Wolak A; Ilia R; Zahger D
Am Heart J; 2006 Nov; 152(5):887.e9-14. PubMed ID: 17070151
[TBL] [Abstract][Full Text] [Related]
22. Large and small vessel vasoconstriction following coronary artery stenting. Effect of intra coronary nitroglycerine and relation to LDL cholesterol.
Larsen AI; Basran R; Anderson T; Goodhart D;
Int J Cardiol; 2006 Oct; 113(1):61-5. PubMed ID: 16337702
[TBL] [Abstract][Full Text] [Related]
23. [Coronary dilatation after intracoronary administration of SIN-1 and intravenous molsidomine administration].
Hug J; Hasenfuss G; Wollschläger H; Just HJ; Bonzel T
Med Klin (Munich); 1994 Jul; 89 Suppl 2():34-7. PubMed ID: 7968899
[No Abstract] [Full Text] [Related]
24. Standardization of coronary vasomotor tone with intracoronary nitroglycerin.
Jost S; Sturm M; Hausmann D; Lippolt P; Lichtlen PR
Am J Cardiol; 1996 Jul; 78(1):120-3. PubMed ID: 8712104
[TBL] [Abstract][Full Text] [Related]
25. Response of normal and diseased epicardial coronary arteries to vasoactive drugs: quantitative arteriographic studies.
Brown BG
Am J Cardiol; 1985 Sep; 56(9):23E-29E. PubMed ID: 3901724
[TBL] [Abstract][Full Text] [Related]
26. SIN-1 has no direct myocardial anti-ischemic action.
Kober G; Bender M; Vallbracht C; Sievert H; Klepzig H
Clin Cardiol; 1993 Oct; 16(10):717-22. PubMed ID: 8222384
[TBL] [Abstract][Full Text] [Related]
27. Active and passive changes in coronary diameter after vasodilation with SIN-1, the active metabolite of molsidomine.
Schulz W; Kober G; Bernauer R; Kaltenbach M
Am Heart J; 1985 Mar; 109(3 Pt 2):694-9. PubMed ID: 3838406
[TBL] [Abstract][Full Text] [Related]
28. The effect of diltiazem on coronary flow reserve in humans.
Rossen JD; Simonetti I; Marcus ML; Braun P; Winniford MD
Circulation; 1989 Nov; 80(5):1240-6. PubMed ID: 2805261
[TBL] [Abstract][Full Text] [Related]
29. Isosorbidedinitrate and SIN-1 as dilators of human coronary arteries and platelet inhibitors.
Bult H; Bosmans JM; Vrints CJ; Herman AG
J Cardiovasc Pharmacol; 1995 Apr; 25(4):572-8. PubMed ID: 7596125
[TBL] [Abstract][Full Text] [Related]
30. How to standardize vasomotor tone in serial studies based on quantitation of coronary dimensions?
Jost S; Nolte CW; Sturm M; Hausleiter J; Hausmann D
Int J Card Imaging; 1998 Dec; 14(6):357-72. PubMed ID: 10453390
[TBL] [Abstract][Full Text] [Related]
31. Long-acting coronary vasodilatory action of the molsidomine metabolite Sin 1: a quantitative angiographic study.
Serruys PW; Deckers JW; Luijten HE; Reiber JH; Tijssen JG; Chadha D; Hugenholtz PG
Eur Heart J; 1987 Mar; 8(3):263-70. PubMed ID: 3582385
[TBL] [Abstract][Full Text] [Related]
32. Intracoronary nisoldipine: effects on acute myocardial ischemia during coronary angioplasty.
Amende I; Herrmann G; Simon R; Wenzlaff P; Lichtlen PR
Cardiovasc Drugs Ther; 1989 Jan; 2(6):807-13. PubMed ID: 2488096
[TBL] [Abstract][Full Text] [Related]
33. [SIN-1 in intracoronary administration].
Schulz W
Presse Med; 1988 May; 17(20):1027-32. PubMed ID: 2969098
[TBL] [Abstract][Full Text] [Related]
34. Response of coronary arteries to nitrates, the EDRF-donor SIN-1, and calcium antagonists.
Schulz W; Kober G
Basic Res Cardiol; 1991; 86 Suppl 2():233-41. PubMed ID: 1953615
[TBL] [Abstract][Full Text] [Related]
35. [Anti-ischemic effects of SIN-1, a molsidomine metabolite, during coronary angioplasty and antiplatelet effects in humans].
Darius H; Erbel E; Schmucker B; Reusch U; Meyer J
Presse Med; 1988 May; 17(20):1033-6. PubMed ID: 2969099
[TBL] [Abstract][Full Text] [Related]
36. Hemodynamic effects of nisoldipine, a highly specific calcium antagonist, in patients with acute myocardial infarction.
Wilson J; Commerford PJ; Millar RS; Opie LH
Cardiovasc Drugs Ther; 1992 Feb; 6(1):41-6. PubMed ID: 1576095
[TBL] [Abstract][Full Text] [Related]
37. Vasodilatory effects of nisoldipine on coronary arteries--correlation with plasma levels.
Jost S; Rafflenbeul W; Mogwitz B; Gulba D; Hecker H; Lichtlen PR
Cardiovasc Drugs Ther; 1990 Feb; 4(1):273-9. PubMed ID: 2285621
[TBL] [Abstract][Full Text] [Related]
38. Coronary-selective properties of nisoldipine.
Deleu D; Vanden Baviere H
Am Heart J; 1992 Jun; 123(6):1726. PubMed ID: 1595567
[No Abstract] [Full Text] [Related]
39. Coronary artery vasomotion and post-stenotic coronary artery blood flow after intracoronary lacidipine in patients with ischaemic heart disease: a pilot study.
Vassanelli C; Menegatti G; Marini A; Beltrame F; Molinari J; Cemin R
Drugs; 1999; 57 Suppl 1():19-26. PubMed ID: 10529079
[TBL] [Abstract][Full Text] [Related]
40. Specific coronary hemodynamic effects of nisoldipine and other vasoactive drugs.
Vrolix M; Piessens J
J Cardiovasc Pharmacol; 1992; 20 Suppl 5():S43-9. PubMed ID: 1282613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
